Details
Stereochemistry | ACHIRAL |
Molecular Formula | C6F14 |
Molecular Weight | 338.0418 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F
InChI
InChIKey=ZJIJAJXFLBMLCK-UHFFFAOYSA-N
InChI=1S/C6F14/c7-1(8,3(11,12)5(15,16)17)2(9,10)4(13,14)6(18,19)20
Molecular Formula | C6F14 |
Molecular Weight | 338.0418 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including:
http://www.ncbi.nlm.nih.gov/books/NBK25382/
Curator's Comment: description was created based on several sources, including:
http://www.ncbi.nlm.nih.gov/books/NBK25382/
Perflexane is a contrast agent for ultrasound Imaging. The mechanism of action of perflexane is an ultrasound contrast activity. Perflexane is a fluorinated hydrocarbon and gaseous substance used as an imaging contrast agent in the echocardiogram. After administration in microsphere form, perflexane increases ultrasound reflectivity of blood. This leads to an improvement of ultrasound signaling. Perflexane-lipid microspheres (AFO150) is a preparation of perfluorocarbon (PFC)-based micro bubbles it was approved by the Food and Drug Administration in 2002 for clinical use in echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border. However, AFO150 is not currently available for clinical applications.
Approval Year
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
26.3 ng/mL |
20 μg/kg bw single, intravenous dose: 20 μg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered: |
PERFLEXANE blood | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
11.3 ng × h/mL |
20 μg/kg bw single, intravenous dose: 20 μg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered: |
PERFLEXANE blood | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
5.7 h |
20 μg/kg bw single, intravenous dose: 20 μg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered: |
PERFLEXANE blood | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
5.3 h |
20 μg/kg bw single, intravenous dose: 20 μg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered: |
PERFLEXANE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
PubMed
Title | Date | PubMed |
---|---|---|
Effects of vaporized perfluorocarbon on pulmonary blood flow and ventilation/perfusion distribution in a model of acute respiratory distress syndrome. | 2001 Dec |
|
A possible mechanism of naproxen-induced lipid peroxidation in rat liver microsomes. | 2001 Jul |
|
Carbomethoxychlorocarbene: spectroscopy, theory, chemistry and kinetics. | 2001 Jun 27 |
|
Fluorous triphasic reactions: transportative deprotection of fluorous silyl ethers with concomitant purification. | 2001 Oct 17 |
|
AFO 150. Imagent, Imavist. | 2002 |
|
Improvements in the ultrasonic contrast of targeted perfluorocarbon nanoparticles using an acoustic transmission line model. | 2002 Jan |
|
Changes in pulmonary function and oxygenation during application of perfluorocarbon vapor in healthy and oleic acid-injured animals. | 2002 Jun |
|
Phase-vanishing reactions that use fluorous media as a phase screen. Facile, controlled bromination of alkenes by dibromine and dealkylation of aromatic ethers by boron tribromide. | 2002 Nov 6 |
|
A new experimental protocol for intrazeolite photooxidations. The first product-based estimate of an upper limit for the intrazeolite singlet oxygen lifetime. | 2002 Sep 25 |
|
Ultrasound-mediated cavitation thresholds of liquid perfluorocarbon droplets in vitro. | 2003 Sep |
|
Liquid crystalline behavior of a semifluorinated oligomer. | 2004 Dec 8 |
|
[Reduction in the aggressiveness of ventilation by inhalation of perfluorohexane after therapy of oleic acid-induced respiratory failure]. | 2004 Feb |
|
Noninvasive estimation of the pressure gradient across stenoses using sonographic contrast: in vitro validation. | 2004 May |
|
Effect of oxygenated perfluorocarbons on isolated rat pancreatic islets in culture. | 2005 |
|
Comparison of different inhalational perfluorocarbons in a rabbit model of acute lung injury. | 2005 Jan-Feb |
|
Effects of perfluorohexan vapor on gas exchange, respiratory mechanics, and lung histology in pigs with lung injury after endotoxin infusion. | 2005 Sep |
|
Cyclic variation in ultrasonic myocardial integrated backscatter is due to phasic changes in the number of patent myocardial microvessels. | 2006 Aug |
|
Comparative effects of vaporized perfluorohexane and partial liquid ventilation in oleic acid-induced lung injury. | 2006 Feb |
|
Investigating perfluorohexane particles with high-frequency ultrasound. | 2006 Jan |
|
Rate enhancement of Diels-Alder reactions in aqueous perfluorinated emulsions. | 2006 Nov 23 |
|
Raman microspectroscopy/imaging study on phase-vanishing processes of fluorous biphase systems in microchannel-microheater chips. | 2006 Oct |
|
Positive end-expiratory pressure at minimal respiratory elastance represents the best compromise between mechanical stress and lung aeration in oleic acid induced lung injury. | 2007 |
|
Phagocytosis of ultrasound contrast agent microbubbles by Kupffer cells. | 2007 Feb |
|
Exposure of an adult population to perfluorinated substances using duplicate diet portions and biomonitoring data. | 2007 Nov 15 |
|
Structure and depletion at fluorocarbon and hydrocarbon/water liquid/liquid interfaces. | 2008 Aug 15 |
|
Leukocyte antibacterial functions are not impaired by perfluorocarbon exposure in vitro. | 2008 Jul |
|
Influence of collection solvent on permeation of di-n-octyl disulfide through nitrile glove material. | 2008 Mar 1 |
|
Solvation of halogens in fluorous phases. Experimental and simulation data for F2, Cl2, and Br2 in several fluorinated liquids. | 2008 May 29 |
|
Perfluorohexane-loaded macrophages as a novel ultrasound contrast agent: a feasibility study. | 2008 Sep |
|
The multi-vicinal fluoroalkane motif: an examination of 2,3,4,5-tetrafluorohexane stereoisomers. | 2008 Sep 7 |
|
Reverse water-in-fluorocarbon microemulsions stabilized by new polyhydroxylated nonionic fluorinated surfactants. | 2009 Aug 18 |
|
Environmental hazards and health risk of common liquid perfluoro-n-alkanes, potent greenhouse gases. | 2009 Feb |
|
Polyfluoroalkyl chemicals in the serum and milk of breastfeeding women. | 2009 Jun |
|
A novel and stable "two-hit" acute lung injury model induced by oleic acid in piglets. | 2009 Mar 30 |
|
Perfluorinated compounds in delivering women from south central Vietnam. | 2009 Nov |
|
Gels from a semifluorinated n-alkane in fluorinated solvents as a probe for intermolecular interactions. | 2009 Nov 1 |
|
A new method for the preparation of monoporous hollow microspheres. | 2010 Apr 6 |
|
Pretreatment with perfluorohexane vapor attenuates fMLP-induced lung injury in isolated perfused rabbit lungs. | 2010 Aug |
|
Controlling the thickness of hollow polymeric microspheres prepared by electrohydrodynamic atomization. | 2010 Aug 6 |
|
Delivery of water-soluble drugs using acoustically triggered perfluorocarbon double emulsions. | 2010 Dec |
|
Sonochemical synthesis of liquid-encapsulated lysozyme microspheres. | 2010 Feb |
|
Phospholipid-coated gas bubble engineering: key parameters for size and stability control, as determined by an acoustical method. | 2010 Feb 2 |
|
Permeation of a metalworking fluid through a latex glove under field use conditions. | 2010 Jan |
|
Systemic perfluorohexane attenuates lung injury induced by lipopolysaccharide in rats: the role of heme oxygenase-1. | 2010 Jan-Feb |
|
Female scent signals enhance the resistance of male mice to influenza. | 2010 Mar 1 |
|
Pilot study of vaporization of perfluorohexane during high-frequency oscillatory ventilation in experimental acute lung injury. | 2010 Nov |
|
Effects of perfluorohexane vapor in the treatment of experimental lung injury. | 2010 Oct |
Sample Use Guides
The recommended dose is 0.00625 mL/kg (0.125 mg/kg) administered as a single intravenous bolus over a period of not less than 10 seconds and immediately followed by a saline flush. Imagent (The active moiety, the microsphere, comprises two critical components: perflexane, the gaseous component, and DMPC, the lipid membrane component) must be used within 30 minutes of reconstitution.
Route of Administration:
Intravenous
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:59:36 GMT 2023
by
admin
on
Fri Dec 15 15:59:36 GMT 2023
|
Record UNII |
FX3WJ41CMX
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000010259
Created by
admin on Fri Dec 15 15:59:36 GMT 2023 , Edited by admin on Fri Dec 15 15:59:36 GMT 2023
|
||
|
CFR |
21 CFR 173.342
Created by
admin on Fri Dec 15 15:59:36 GMT 2023 , Edited by admin on Fri Dec 15 15:59:36 GMT 2023
|
||
|
NDF-RT |
N0000175864
Created by
admin on Fri Dec 15 15:59:36 GMT 2023 , Edited by admin on Fri Dec 15 15:59:36 GMT 2023
|
||
|
NCI_THESAURUS |
C1937
Created by
admin on Fri Dec 15 15:59:36 GMT 2023 , Edited by admin on Fri Dec 15 15:59:36 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C078626
Created by
admin on Fri Dec 15 15:59:36 GMT 2023 , Edited by admin on Fri Dec 15 15:59:36 GMT 2023
|
PRIMARY | |||
|
39427
Created by
admin on Fri Dec 15 15:59:36 GMT 2023 , Edited by admin on Fri Dec 15 15:59:36 GMT 2023
|
PRIMARY | |||
|
1540828
Created by
admin on Fri Dec 15 15:59:36 GMT 2023 , Edited by admin on Fri Dec 15 15:59:36 GMT 2023
|
PRIMARY | RxNorm | ||
|
SUB33239
Created by
admin on Fri Dec 15 15:59:36 GMT 2023 , Edited by admin on Fri Dec 15 15:59:36 GMT 2023
|
PRIMARY | |||
|
FX3WJ41CMX
Created by
admin on Fri Dec 15 15:59:36 GMT 2023 , Edited by admin on Fri Dec 15 15:59:36 GMT 2023
|
PRIMARY | |||
|
PERFLUOROHEXANE
Created by
admin on Fri Dec 15 15:59:36 GMT 2023 , Edited by admin on Fri Dec 15 15:59:36 GMT 2023
|
PRIMARY | |||
|
100000126369
Created by
admin on Fri Dec 15 15:59:36 GMT 2023 , Edited by admin on Fri Dec 15 15:59:36 GMT 2023
|
PRIMARY | |||
|
9639
Created by
admin on Fri Dec 15 15:59:36 GMT 2023 , Edited by admin on Fri Dec 15 15:59:36 GMT 2023
|
PRIMARY | |||
|
FX3WJ41CMX
Created by
admin on Fri Dec 15 15:59:36 GMT 2023 , Edited by admin on Fri Dec 15 15:59:36 GMT 2023
|
PRIMARY | |||
|
DB09531
Created by
admin on Fri Dec 15 15:59:36 GMT 2023 , Edited by admin on Fri Dec 15 15:59:36 GMT 2023
|
PRIMARY | |||
|
m8541
Created by
admin on Fri Dec 15 15:59:36 GMT 2023 , Edited by admin on Fri Dec 15 15:59:36 GMT 2023
|
PRIMARY | Merck Index | ||
|
7871
Created by
admin on Fri Dec 15 15:59:36 GMT 2023 , Edited by admin on Fri Dec 15 15:59:36 GMT 2023
|
PRIMARY | |||
|
355-42-0
Created by
admin on Fri Dec 15 15:59:36 GMT 2023 , Edited by admin on Fri Dec 15 15:59:36 GMT 2023
|
PRIMARY | |||
|
7917
Created by
admin on Fri Dec 15 15:59:36 GMT 2023 , Edited by admin on Fri Dec 15 15:59:36 GMT 2023
|
PRIMARY | |||
|
DTXSID7046548
Created by
admin on Fri Dec 15 15:59:36 GMT 2023 , Edited by admin on Fri Dec 15 15:59:36 GMT 2023
|
PRIMARY | |||
|
CHEMBL1200607
Created by
admin on Fri Dec 15 15:59:36 GMT 2023 , Edited by admin on Fri Dec 15 15:59:36 GMT 2023
|
PRIMARY | |||
|
KK-122
Created by
admin on Fri Dec 15 15:59:36 GMT 2023 , Edited by admin on Fri Dec 15 15:59:36 GMT 2023
|
PRIMARY | |||
|
3429
Created by
admin on Fri Dec 15 15:59:36 GMT 2023 , Edited by admin on Fri Dec 15 15:59:36 GMT 2023
|
PRIMARY | |||
|
206-585-0
Created by
admin on Fri Dec 15 15:59:36 GMT 2023 , Edited by admin on Fri Dec 15 15:59:36 GMT 2023
|
PRIMARY | |||
|
C47663
Created by
admin on Fri Dec 15 15:59:36 GMT 2023 , Edited by admin on Fri Dec 15 15:59:36 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |